EE50 Olaparib As Maintenance Therapy for Women with Ovarian Cancer and Homologous Recombination Deficiency in Brazil: What Clinical and Cost Data Have Highest Impact on Cost-Effectiveness Analysis?
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.304
https://www.valueinhealthjournal.com/article/S1098-3015(22)00505-8/fulltext
Title :
EE50 Olaparib As Maintenance Therapy for Women with Ovarian Cancer and Homologous Recombination Deficiency in Brazil: What Clinical and Cost Data Have Highest Impact on Cost-Effectiveness Analysis?
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00505-8&doi=10.1016/j.jval.2022.04.304
First page :
Section Title :
Open access? :
No
Section Order :
10265